Berridge T L, Roach A G
Br J Pharmacol. 1986 Jun;88(2):345-54. doi: 10.1111/j.1476-5381.1986.tb10210.x.
alpha-Adrenoceptors present in the vasculature of the nasal mucosa in beta-adrenoceptor blocked dogs have been characterized pharmacologically using selective alpha 1- and alpha 2-adrenoceptor agonists and antagonists. In pentobarbitone-anaesthetized dogs, intra-arterial (i.a.) administration of the selective alpha 1-agonists cirazoline and phenylephrine, the selective alpha 2-agonist UK-14,304 and the mixed alpha 1/alpha 2-agonists adrenaline, noradrenaline and oxymetazoline produced dose-related nasal vasoconstrictor responses (as measured by decreases in nasal cavity pressure). The rank order of agonist potency was adrenaline greater than oxymetazoline = UK-14,304 greater than noradrenaline greater than cirazoline greater than phenylephrine. The nasal response to cirazoline was inhibited by the selective alpha 1-adrenoceptor antagonist prazosin but not by the new, potent selective alpha 2-adrenoceptor antagonist RX811059. In contrast, UK-14,304 was inhibited only by RX811059. Either prazosin or RX811059 reduced the effect of the mixed agonist adrenaline. In spinal dogs, the noradrenaline-evoked fall in nasal cavity pressure was reduced by either prazosin or RX811059. Prazosin attenuated markedly the nasal vasoconstrictor response to electrical stimulation of postganglionic fibres emerging from the superior cervical ganglion (SNS) whereas RX811059 was ineffective. Administration of the neuronal re-uptake inhibitor cocaine potentiated the effect of i.a. noradrenaline but reduced marginally the maximal response to SNS. After cocaine, RX811059 enhanced the effect of SNS and attenuated the response to noradrenaline. Prazosin reduced effectively the responses to both SNS and noradrenaline after cocaine. Pretreatment with the alpha 2-agonist UK-14,304 did not affect the response to noradrenaline in the nasal cavity but evoked a persistent (up to 2 h) reduction in the response to SNS. RX811059 antagonized the inhibitory effect of UK-14,304. These results demonstrate that both postjunctional alpha 1- and alpha 2-adrenoceptors mediating vasoconstriction are present in the canine nasal mucosa. In addition, sympathetic neurones innervating the nasal mucosa are characterized by a very efficient re-uptake process and contain prejunctional alpha 2-adrenoceptors.
在β-肾上腺素能受体被阻断的犬类鼻黏膜血管系统中存在的α-肾上腺素能受体,已使用选择性α1和α2肾上腺素能激动剂及拮抗剂进行了药理学特征描述。在戊巴比妥麻醉的犬类中,动脉内(i.a.)给予选择性α1激动剂西拉唑啉和去氧肾上腺素、选择性α2激动剂UK-14,304以及混合性α1/α2激动剂肾上腺素、去甲肾上腺素和羟甲唑啉,产生了剂量相关的鼻血管收缩反应(通过鼻腔压力降低来测量)。激动剂效力的排序为肾上腺素>羟甲唑啉 = UK-14,304>去甲肾上腺素>西拉唑啉>去氧肾上腺素。西拉唑啉引起的鼻腔反应被选择性α1肾上腺素能受体拮抗剂哌唑嗪抑制,但未被新型强效选择性α2肾上腺素能受体拮抗剂RX811059抑制。相反,UK-14,304仅被RX811059抑制。哌唑嗪或RX811059均可降低混合激动剂肾上腺素的作用。在脊髓犬中,哌唑嗪或RX811059均可降低去甲肾上腺素引起的鼻腔压力下降。哌唑嗪显著减弱了对颈上神经节(SNS)发出的节后纤维进行电刺激所引起的鼻血管收缩反应,而RX811059则无效。给予神经元再摄取抑制剂可卡因可增强动脉内去甲肾上腺素的作用,但略微降低了对SNS的最大反应。给予可卡因后,RX811059增强了SNS的作用并减弱了对去甲肾上腺素的反应。哌唑嗪有效降低了给予可卡因后对SNS和去甲肾上腺素的反应。用α2激动剂UK-14,304预处理不影响鼻腔对去甲肾上腺素的反应,但引起对SNS反应的持续(长达2小时)降低。RX811059拮抗了UK-14,304的抑制作用。这些结果表明,介导血管收缩的节后α1和α2肾上腺素能受体均存在于犬类鼻黏膜中。此外,支配鼻黏膜的交感神经元具有非常有效的再摄取过程,并含有节前α2肾上腺素能受体。